Arbutus Biopharma (ABUS) has released an update.
Arbutus Biopharma and Barinthus Bio have reported promising new data from their IM-PROVE II trial, indicating that the addition of nivolumab to their treatment regimen significantly increased the rate of HBsAg loss in individuals with chronic Hepatitis B. The combination treatment led to a notable 23% of participants achieving HBsAg loss by the 48th week.
For further insights into ABUS stock, check out TipRanks’ Stock Analysis page.
